相关临床试验
8
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2014
进行中（未招募）
2
25.0%
已完成
1
12.5%
招募中
5
62.5%
暂无批准数据
- BioGene Therapeutics has appointed Ty Howton, a nearly 30-year biopharmaceutical industry veteran, to its Board of Directors effective immediately. - Howton brings extensive experience scaling gene therapy and precision medicine companies from clinical to commercial stages, including leadership roles at Solid Biosciences, Sarepta Therapeutics, and Vertex Pharmaceuticals. - The appointment includes 100,000 stock options exercisable at $5.00 per share through June 2031 and 500,000 restricted share units, both vesting in 25% annual increments over four years. - BioGene is advancing gene therapies targeting metabolic health, including GLP-1 receptor agonists and treatments for diabetes and obesity through its Australian subsidiary.
- Solid Biosciences received FDA Rare Pediatric Disease designation for SGT-212, its investigational gene therapy for Friedreich's ataxia, providing eligibility for a priority review voucher upon approval. - The company's lead program SGT-003 for Duchenne muscular dystrophy entered the UK's Innovation Licensing and Access Pathway (ILAP) and is being evaluated in the Phase 1/2 INSPIRE DUCHENNE trial. - Duchenne muscular dystrophy was added to the U.S. Department of Health and Human Services' Recommended Uniform Screening Panel, expected to accelerate nationwide newborn screening. - Solid entered a worldwide license agreement with Andelyn Biosciences for its proprietary AAV-SLB101 capsid, which demonstrated favorable tolerability in pediatric participants and robust muscle transduction.
- The Duchenne Muscular Dystrophy market reached approximately $2.15 billion in 2023 and is expected to grow significantly due to increased drug uptake and anticipated gene therapy launches. - Over 75 companies are actively developing pipeline therapies for DMD, with recent FDA designations including Atossa Therapeutics' (Z)-Endoxifen receiving Rare Pediatric Disease designation. - Capricor Therapeutics announced positive Phase 3 HOPE-3 trial results for Deramiocel, while the FDA accepted their BLA for review with Priority Review designation. - Current approved treatments include EMFLAZA, VYONDYS 53, EXONDYS 51, AMONDYS 45, VILTEPSO, and gene therapy ELEVIDYS in the US, with AGAMREE launched in Germany in 2024.
- Solid Biosciences received FDA Rare Pediatric Disease and Fast Track designations for SGT-212, a dual-route gene therapy targeting Friedreich's ataxia. - SGT-212 represents the only gene therapy in development using both intradentate nucleus and intravenous delivery routes to restore frataxin protein levels. - The designation provides potential access to a pediatric priority review voucher and enhanced FDA engagement for the FALCON Phase 1b trial currently screening participants. - Friedreich's ataxia affects approximately 5,000 people in the United States with no current treatments available to cure or halt disease progression.
- Kinea Bio secured up to $1.1 million from the Jain Foundation to support critical preclinical studies for KNA-155, a dual-AAV gene therapy targeting dysferlinopathy. - The company licensed Solid Biosciences' proprietary AAV-SLB101 capsid, which demonstrates enhanced muscle tropism and reduced liver uptake for safer systemic delivery. - These strategic partnerships provide the scientific and financial foundation to accelerate development of KNA-155 toward first-in-human trials for patients with this progressive muscular dystrophy. - AAV-SLB101 has shown promising safety data in 15 participants from Solid's ongoing Phase 1/2 INSPIRE DUCHENNE trial as of August 2025.
- Solid Biosciences has received FDA IND and Health Canada CTA approval for SGT-501, a novel gene therapy designed to treat catecholaminergic polymorphic ventricular tachycardia (CPVT), a rare genetic heart condition that can cause sudden death. - SGT-501 represents the first potential therapy to address the underlying mechanisms of CPVT by delivering a functional copy of the CASQ2 gene to stabilize calcium regulation in heart muscle cells. - The company plans to initiate a Phase 1b clinical trial in the fourth quarter of 2025, marking a significant milestone for patients with this life-threatening condition that currently has no approved treatments. - CPVT affects approximately 1 in 10,000 individuals globally and is often triggered by physical activity or emotional stress, leading to dangerous arrhythmias in otherwise healthy hearts.
- Peter Marks, head of FDA's Center for Biologics Evaluation and Research since 2016, was forced to resign after refusing to support HHS Secretary Robert F. Kennedy Jr.'s vaccine safety claims. - The departure triggered significant stock declines for gene therapy and vaccine-focused companies including Taysha, Solid Biosciences, Sarepta and Novavax, with shares falling 5-10%. - Industry leaders express concern that FDA's scientific independence is under threat, with BMO Capital Markets analysts calling the resignation "a significant negative for the biopharma and biotech sectors." - Marks' exit follows other key FDA departures, including CDER head Patrizia Cavazzoni, raising questions about regulatory stability and the future of accelerated approvals for innovative therapies.
• The FDA has cleared Solid Biosciences' IND for SGT-212, a gene therapy targeting both neurological and cardiac manifestations of Friedreich's ataxia. • SGT-212 utilizes a dual route of administration, delivering full-length frataxin to the cerebellum via IDN infusion and to the heart via IV infusion. • A Phase 1b trial is planned for the second half of 2025, assessing safety and tolerability in ambulatory and non-ambulatory adults with FA over five years. • SGT-212 aims to address the underlying mitochondrial dysfunction in neurons and cardiomyocytes by restoring frataxin levels.
• The FDA granted breakthrough therapy designation to STK-001 for Dravet syndrome, highlighting its potential to improve upon current treatments by restoring NaV1.1 protein levels. • Tolebrutinib received breakthrough therapy designation for non-relapsing secondary progressive multiple sclerosis based on phase 3 trial results showing delayed disability progression. • The FDA placed a clinical hold on PepGen’s PGN-EDO51 phase 2 study for Duchenne muscular dystrophy, pending further clarification from the agency.
• AbbVie's Vyalev, a 24-hour subcutaneous levodopa infusion, gained FDA approval for managing motor fluctuations in advanced Parkinson's, offering a novel therapeutic approach. • Intellia's CRISPR therapy, NTLA-2001, demonstrated safe redosing in ATTR amyloidosis patients, achieving additive pharmacodynamic effects on the target protein. • A phase 3 study revealed that buntanetap is a safe and well-tolerated drug which improves motor, nonmotor, and cognitive symptoms of Parkinson's disease. • The FDA supported using αSyn-SAA biomarker in Parkinson's clinical trials, enhancing therapeutic development through improved diagnostic precision.
